Verified employee & interview reviews

Anthem Biosciences Reviews

Bengaluru, Karnataka

4.0/ 5

1 review

Anthem Biosciences Limited is a prominent, technology-focused Contract Research, Development, and Manufacturing Organization (CRDMO) headquartered in Bengaluru, India. Established in June 2006 by founders Ajay Bharadwaj, Ganesh Sambashivam, and K. Ravindra Chandrappa, the company has grown into an innovation-driven, fully integrated service provider spanning the entire drug discovery, development, and commercial manufacturing value chain. Following a successful Initial Public Offering (IPO) in July 2025, Anthem transitioned into a publicly traded corporate entity listed on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) under the ticker symbol ANTHEM. The company is distinguished as one of the few operators in India possessing comprehensive and integrated capabilities in both New Chemical Entity (NCE) small molecules and New Biological Entity (NBE) large molecules. Anthem operates through two primary business segments: Contract Research, Development & Manufacturing (CRDMO) services, and Specialty Ingredients. Its diverse operational portfolio covers early-stage target identification, preclinical evaluation, process synthesis, and analytical R&D, moving seamlessly into scale-up and cGMP commercial production. It serves a global clientele composed of innovator-focused emerging biotech firms and top-tier global pharmaceutical companies. Anthem’s scientific expertise covers complex modalities, including small molecules, monoclonal antibodies (mAbs), peptides, oligonucleotides, antibody-drug conjugates (ADCs), lipids, and RNA-based therapies. In its Specialty Ingredients segment, the company manufactures and markets fermentation-based active pharmaceutical ingredients (APIs) such as serratiopeptidase, vitamin K2, enzymes, probiotics (including Bacillus and Lactobacillus strains), and advanced biosimilars. Operationally, Anthem operates out of world-class, state-of-the-art facilities located primarily around Bengaluru, including major footprints in the Bommasandra Industrial Area and Harohalli. These units hold rigorous international regulatory approvals from global bodies, including the United States FDA, Japan's PMDA, Brazil's ANVISA, Australia's TGA, and Health Canada. Strategically, Anthem has implemented a 'China-plus-one' supply chain framework, ensuring minimal dependence on Chinese raw materials to enhance supply security for its global partners. Financially, Anthem Biosciences maintains a robust balance sheet characterized by negligible debt and strong returns, with a trailing twelve-month revenue of approximately $240 million and a market capitalization exceeding ₹42,000 crore. As of 2026, the company employs over 2,000 skilled professionals, including a massive contingent of scientists, researchers, and engineers. Led by Executive Chairman and CEO Ajay Bharadwaj, alongside Chief Scientific Officer Ganesh Sambashivam and Chief Operating Officer K. Ravindra Chandrappa, Anthem continues to expand its manufacturing capabilities—particularly in large-scale fermentation and synthetic peptides—positioning itself as a premier, high-quality, and compliant one-stop alternative in the global biopharma outsourcing ecosystem.